Ditchcarbon
  • Contact
  1. Organizations
  2. CSL Behring GmbH
Public Profile
Pharmaceutical Preparation Manufacturing
AT
updated a month ago

CSL Behring GmbH Sustainability Profile

Company website

CSL Behring GmbH, a leading global biotechnology company, is headquartered in Austria (AT) and operates extensively across Europe, North America, and Asia. Founded in 1904, CSL Behring has established itself as a pioneer in the development of innovative therapies for rare and serious medical conditions, particularly in the fields of immunology, haematology, and respiratory health. The company is renowned for its high-quality plasma-derived therapies, including immunoglobulins and clotting factor concentrates, which are essential for patients with immune deficiencies and bleeding disorders. CSL Behring's commitment to research and development has positioned it as a market leader, with notable achievements in advancing treatment options and improving patient outcomes. With a strong focus on patient care and scientific excellence, CSL Behring continues to make significant contributions to the biopharmaceutical industry.

DitchCarbon Score

How does CSL Behring GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

49

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

CSL Behring GmbH's score of 49 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.

68%

Let us know if this data was useful to you

CSL Behring GmbH's reported carbon emissions

Inherited from CSL Limited

CSL Behring GmbH, headquartered in Austria (AT), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of CSL Limited, which may influence its climate commitments and reporting practices. CSL Limited, the parent organisation, has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for CSL Behring GmbH have not been disclosed. As a subsidiary, CSL Behring GmbH's climate commitments may align with those of CSL Limited, which is focused on reducing its carbon footprint and enhancing sustainability practices across its operations. The absence of direct emissions data suggests that CSL Behring GmbH is still in the process of developing its own specific climate strategies or reporting frameworks. In summary, while CSL Behring GmbH does not currently provide emissions data or specific reduction targets, it is part of a corporate family that is actively engaged in climate initiatives through its parent company, CSL Limited.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20182019202020212022202320242025
Scope 1
250,000,000
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
58,000,000
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
-
-
-
-

How Carbon Intensive is CSL Behring GmbH's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. CSL Behring GmbH's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is CSL Behring GmbH's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for CSL Behring GmbH is in AT, which has a very low grid carbon intensity relative to other regions.

CSL Behring GmbH's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

CSL Behring GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare CSL Behring GmbH's Emissions with Industry Peers

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated 22 minutes ago

Salix Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 21 days ago

Shire plc

IE
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Dyax Corp.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Takeda Pharmaceuticals U.S.A., Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

BCR

CR
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy